The End of OncoSure, For Now
The OncoSure project was started in September 2022 with the ambitious goal of providing direct-to-consumer cancer screening through a subscription service for at-home, non-invasive blood sample collection. We aimed to utilise existing FDA-approved non-invasive blood collection technology to enable convenient and regular risk screening for 50 different cancer types in the comfort of a patient's home. These predictions were to be made using high-throughput machine learning-assisted analysis of methylation patterns on DNA fragments shed by tumors into circulation.
In October 2022, our startup progressed through to the Semi-Final round of the MedTech Actuator Origin. This is Asia-Pacific’s MedTech Incubator and afforded us the opportunity to pressure test our business plan, develop our business acumen and liaise with experts in medical technology, artificial intelligence, commercialisation and intellectual property. However, after speaking to various key stakeholders and experts in the field, my co-founder and I decided to pause further work on this project while we focus on completing our research degrees.
